TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Reduction of RV pulse pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean Breteau index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: MRF reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: plasma ANP concentration decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: TGF-β concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cumulative probability to become normal glucose tolerant (NGT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cumulative incidence of diabetes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: total symptomatic days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: nights of sleep disturbance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Episodes of anemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean conjugated dienes in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean TBARS in serum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in health status (RAND-GHRI)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Advancement of sleep onset
Endpoint domain: Physiological/clinical
Endpoint subdomain: Sleep
Primary endpoint: Decrease in sleep latency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Sleep
Primary endpoint: Mean number of cramps
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of abnormal FHR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of subsequent intrauterine resuscitations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Rod photoreceptor sensitivity suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SP-D levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LV mass indexed to body surface area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean IOP after 2 years
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: cynicism
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: positive expectations for clients
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Serum visfatin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum IL-6 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: recurrence rate of genital herpes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: treatment of pediatric upper respiratory tract infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Reduction in plaque index (API)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in bleeding index (PBI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in gingival index (QHI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: related deaths
Endpoint domain: Mortality/survival
Primary endpoint: Lymphocyte DNA damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: identity shift
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: improved pulmonary function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: significant hypercoagulability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: reduced incidence of vomiting
Endpoint domain: Adverse events/effects
Primary endpoint: plaque levels reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean arterial attenuation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: image quality scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Summative scores of the novel system
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients in remission at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients maintaining SDAI≤2 at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Remission duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in plasma Trp‐LNAA ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Improvement in memory scanning
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: mean reflective total nasal symptom score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Psychomotor performance impairment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: increase in bone mineral content
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: mortality rate at day 14
Endpoint domain: Mortality/survival
Primary endpoint: Glycaemic lability index (GLI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: phonophobia free
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: photophobia free
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: nausea free
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in Systolic Blood Pressure (SAP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Decrease in Diastolic Blood Pressure (DAP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: withdrawal symptom scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thigh muscle volume deficit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Quadriceps peak torque deficit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Maximal isometric quadriceps deficit
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: unplanned cardiovascular hospitalisation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: death from rectal cancer
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of acH4-positive myeloid cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of fracture
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of hip fractures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: catheter failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Incidence of bleeding at the stapled line
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Success rate at 12-month follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Function of affected upper extremities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activity of daily living
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: CINV severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Karnofsky score improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Normalization of vitamin D levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parathyroid hormone levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: In-hospital mortality rate
Endpoint domain: Mortality/survival
Primary endpoint: Grip and pinch strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postflight tachycardia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement in Modified Marshall score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in IL-6 concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Proportion of patients maintaining viral load <50 copies/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood lactate concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Access to ERT
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Incidence of Fabry disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Monitoring patients' progress
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of wound size
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient-rated efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Healing time of wounds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Sudden death and/or sustained ventricular tachycardia (SVT)
Endpoint domain: Mortality/survival
Primary endpoint: Nonsustained ventricular tachycardia (NSVT) incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: HBeAg seroconversion rate at week 72
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Gain in BMI
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Loss of lumbar BMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Gain in total and lower limb fat mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative cardiac event rate
Endpoint domain: Mortality/survival
Primary endpoint: Retention of the acid-etch group
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Caries preventive effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Oxygen pulse
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: mean serum 6‐beta‐naltrexol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ratings of sedation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: ratings of liking and best effects
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: mTICI ≥2b within 3 passes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: All-cause mortality at 90 days
Endpoint domain: Mortality/survival
Primary endpoint: decreased edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: decreased erythema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: increased expression of basic fibroblast growth factor (bFGF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: morphine requirements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean time to complete epithelial healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean pain scores
Endpoint domain: Adverse events/effects
Primary endpoint: Aspiration thrombectomy success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reinfarction rate
Endpoint domain: Adverse events/effects
Primary endpoint: Central macular thickness (CMT) reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pulp breakdown
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of reinfarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Duration of symptoms in tonsillitis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Risk of reinfections
Endpoint domain: Adverse events/effects
Primary endpoint: time taken for oocyte recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: dose of pethidine required
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Healthy eating behaviors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Insulin Sensitivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Reduction in haemoglobin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Need for transfusion
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction in tooth darkness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete lysis (95% or more)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total time to review caseloads
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Propulsive velocity during SQ exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Negative side effects of caffeine
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of PONV (Postoperative Nausea and Vomiting)
Endpoint domain: Adverse events/effects
Primary endpoint: biochemical response (nadir PSA < 1 after 12 months, < 2 after 6 months)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of late rectal morbidity (grade 2 and 3)
Endpoint domain: Adverse events/effects
Primary endpoint: incidence of late bladder morbidity (grade 2 and 3)
Endpoint domain: Adverse events/effects
Primary endpoint: Total aspirin absorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adaptive capabilities of the autonomic nervous system
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: OPTION scale score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: ACEPP items score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Confidence measure score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: bioequivalence based on the rate and extent of absorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tolerance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean OI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: PaO2/FiO2 area under the curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Acid-related dyspepsia (ARD) score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: relapse criteria met
Endpoint domain: Adverse events/effects
Primary endpoint: Positive and Negative Syndrome Scale total score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: motor UPDRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: walk time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tapping right hand
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tapping left hand
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative horizontal deviation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Definite Lyme disease contraction
Endpoint domain: Mortality/survival
Primary endpoint: Asymptomatic B. burgdorferi infection prevention
Endpoint domain: Mortality/survival
Primary endpoint: Bone alkaline phosphatase levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Bone mineral content
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in AROM
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ISS-RV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lower limb venous flow velocities
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Percent increase in FEV1 over baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: LDAEP (60‐100 dB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: platelet function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: final score correlation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: match success rates
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Mucosal injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Percent atheroma volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Performance on primary suturing tasks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mental workload
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: BIS index recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Maximal power output
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: VO(2) max
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Coronary patency rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: mean decrease in HADS-A score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Acceptability of the Î±‐stat approach
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: mean parenteral morphine consumption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: joint pain relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: physical function improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: daily self-care activities improvement
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Knowledge of the OAR
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: improvement in shoulder pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: all-cause mortality/all-cause hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: N-terminal proANP levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: lower complaint scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: significantly less coughing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: shorter total procedure time
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: First major cardiovascular event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: worsening heart failure (HF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in systolic and diastolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Decrease in neutrophil count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: CD4+ cell count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: plasma levels of HIV-1 RNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Improvement in communication during treatment decision-making consultations
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Purchasing of fruits and vegetables (F&V)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Intake of fruits and vegetables (F&V)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Subjective responses to neuroleptics
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction in the risk of advanced AMD
Endpoint domain: Mortality/survival
Primary endpoint: Rate of bilateral blindness from AMD
Endpoint domain: Mortality/survival
Primary endpoint: Detection of pulmonary, mediastinal, and pleural abnormalities
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Aerobic capacity improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle function improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle composition improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes